Monday, December 06, 2021

NEWS

US magazine praises Cuba´s Soberana 02 vaccine candidate

US magazine praises Cuba´s Soberana 02 vaccine candidate

Washington, Jul 6 (Prensa Latina) Design, obtaining and preclinical assessment of Cuban anti-Covid Soberana 02 vaccine candidate reached the headlines of the US magazine ACS Chemical Biology, paving the way for other antiviral vaccines.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

The technological platform of this vaccine candidate -developed by the Finlay Vaccine Institute (IFV)- is based on macromolecular constructions with a recombinant receptor-binding domain (RBD) conjugated with tetanus toxoid (TT) and induces a powerful immune response in lab animals.

The US magazine, belonging to the American Chemical Society, noted among the advantages of immunization with RBD-TT conjugates a predominant IgG immunoglobulin defense due to affinity maturation and specific long-term memory B cells (lymphocytes).

In this regard, PhD in Sciences Dagmar García, IFV’s Research Director, specified on Facebook that she sent the article on April 11, 2020, and its publication revealed that it took three months for arbitration, review, correction and disclosure. ‘It is an excellent example that summarizes the collaboration of scientists from various Cuban and foreign institutions, who have been a great team in this year of hard work to enforce the science we do in Cuba,’ Garcia stated.

pgh/Pll/oda / nmr

RELATED
ÚLTIMO MINUTO
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.